Genetech announced results from CLL11, a Phase 3 study of obinutuzumab (GA101), comparing the combination of either obinutuzumab or Rituxan and chlorambucil to chlorambucil alone in chronic lymphocytic leukemia (CLL).
Gilead announced Phase 2 results for idelalisib, an oral inhibitor of PI3K delta in combination with rituximab for older patients with treatment-naïve chronic lymphocytic leukemia.
The FDA has accepted Seattle Genetics' sBLA for filing of Adcetris for retreatment and extended duration beyond 16 cycles of therapy in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma.
Leukemia experts call for examination of the 'right' way to price life-saving drugs
For patients with chronic neutrophilic leukemia and atypical chronic myeloid leukemia, activating mutations in the gene encoding the colony stimulating factor 3 receptor are common.
A monoclonal antibody has been found to be cytotoxic to chronic lymphocytic leukemia B cells while having little effect on normal B cells.
Chronic fatigue is more than three times more prevalent among adult survivors of childhood leukemia or lymphoma than among other adults.
Treatment with autologous engineered T cells is effective bridge to potentially curative therapy
Inhibiting the protein receptor Mer destroys cancer cells and enhances chemotherapy in both acute myeloid and acute lymphoblastic leukemia.
Specially treated T cells infused into high-risk and relapsed leukemia patients can prolong survival after stem cell transplantation.
Molecules in the bloodstream that might accurately gauge the likelihood of radiation illness after exposure to ionizing radiation have been identified. This animal study shows that X-rays or gamma rays alter the levels of certain molecules called microRNA (miRNA) in the blood in a predictable way.
Patients with high-risk or relapsed leukemia have been successfully treated with post-stem cell transplantation infusions of large numbers of donor T cells specific for an antileukemic antigen key to prolonging survival, both from the same matched donors.
Persons who have undergone cytotoxic chemotherapy for certain cancers, notably non-Hodgkin lymphoma, may develop acute myeloid leukemia.
Tumors are not factories for the mass production of identical cancer cells, but are, in reality, patchworks of cells with different patterns of gene mutations. A new study shows, more fully than ever before, how these mutations shift and evolve over time.
Removing the Gfi1 protein from acute lymphoid leukemia (ALL) cells weakened and destroyed the cells in mice, researchers discovered.
The risk of developing therapy-related acute myeloid leukemia after chemotherapy varies depending on initial cancer and treatment practices.
Patients undergoing chemotherapy for hematologic cancers are at risk for this complication. The review can help you learn how to assess their risk.
Maintaining a viable population of hematopoietic stem cells may be nearly sufficient to eradicate leukemia stem cells from the system.
Significant reductions seen with successive generations of Hodgkin lymphoma therapy.
The odds of relapse after chemotherapy treatment in young patients with B-precursor acute lymphoblastic leukemia are significantly reduced by administering additional courses of chemotherapy.
Older patients may not respond as well as younger persons to conventional therapies for chronic lymphocytic leukemia, a new study indicates.
Early results of a trial to treat leukemia with WT1 DNA vaccine have shown robust vaccine-specific antibody responses in all vaccinated patients evaluated to date.
Ibrutinib, which targets the Bruton's tyrosine kinase to combat chronic lymphocytic leukemia, showed promising results in two phase II studies.
Leukemia stem cells that overcome drug therapy can be thwarted when deprived of RAD52, a protein key to DNA repair of these cancer cells.
Azacitidine is a DNA methylation inhibitor indicated for the treatment of several FAB myelodysplastic syndrome subtypes.
The American Society of Clinical Oncology has released a nearly 100-page report detailing the year's most significant developments in cancer.
Iclusig (ponatinib) has been approved by the U.S. Food and Drug Administration to treat two rare forms of leukemia.
A previously invincible mutation in chronic myeloid leukemia has been thwarted by the investigational drug, ponatinib, in a phase I clinical trial.
Excessive levels of interleukin-15 initiate large granular lymphocyte (LGL) leukemia, but also represent a promising therapeutic target.
A fusion gene that is responsible for 30% of a rare subtype of childhood leukemia with an extremely poor prognosis has been identified. This finding offers the first evidence of a mistake that gives rise to a significant percentage of acute megakaryoblastic leukemia cases in children.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|